535 total citations 21 papers, 415 citations indexed
About
Mitchell Ms is a scholar working on Immunology, Oncology and Molecular Biology.
According to data from OpenAlex, Mitchell Ms has authored 21 papers receiving a total of 415 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 7 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Mitchell Ms's work include Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (3 papers) and vaccines and immunoinformatics approaches (3 papers). Mitchell Ms is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (3 papers) and vaccines and immunoinformatics approaches (3 papers). Mitchell Ms collaborates with scholars based in United States and Australia. Mitchell Ms's co-authors include Bertino, Papac Rj, Martin Levitt, Thomas Ed, Rose J. Papac, Kaplan, Philip B. Mitchell, Kirkwood Jm, Stephan Ariyan and Chan Kk and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).
In The Last Decade
Mitchell Ms
19 papers
receiving
377 citations
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Mitchell Ms's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell Ms with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell Ms more than expected).
This network shows the impact of papers produced by Mitchell Ms. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell Ms. The network helps show where Mitchell Ms may publish in the future.
Co-authorship network of co-authors of Mitchell Ms
This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell Ms.
A scholar is included among the top collaborators of Mitchell Ms based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Mitchell Ms. Mitchell Ms is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Ms, Mitchell. (1998). Perspective on allogeneic melanoma lysates in active specific immunotherapy.. PubMed. 25(6). 623–35.82 indexed citations
2.
Ms, Mitchell, et al.. (1998). The effect of bioburden on in-depth disinfection of denture base acrylic resin.. PubMed. 26(11). 846–50.6 indexed citations
3.
Ms, Mitchell. (1997). A personal (biased) perspective on cancer "vaccines".. PubMed. 9(9). 459–65.2 indexed citations
4.
Ms, Mitchell. (1995). Regarding breast cancer as an immunologically responsive tumor.. PubMed. 107(3). 279–87.1 indexed citations
5.
Mitchell, Philip B. & Mitchell Ms. (1994). The management of depression. Part 2. The place of the new antidepressants.. PubMed. 23(9). 1771–3, 1776.9 indexed citations
6.
Ms, Mitchell. (1993). Active specific immunotherapy of melanoma: clinical results and correlates.. PubMed. 1(2). 163–79.2 indexed citations
7.
Ms, Mitchell. (1992). Chemotherapy in combination with biomodulation: a 5-year experience with cyclophosphamide and interleukin-2.. PubMed. 19(2 Suppl 4). 80–7.29 indexed citations
8.
Ms, Mitchell. (1989). Active specific immunotherapy in the treatment of human cancers.. PubMed. 288. 323–36.2 indexed citations
9.
Daniëls, et al.. (1986). Recombinant interferon alpha-2 (INTRON A) in a phase II study of renal cell carcinoma.. PubMed. 5(1). 27–35.19 indexed citations
10.
Ms, Mitchell, et al.. (1984). Staphylococcal protein A immunoadsorptive column induces mitogenicity in perfused plasma.. PubMed. 3(3). 235–40.7 indexed citations
11.
Ariyan, Stephan, et al.. (1982). Intralymphatic and regional surgical adjuvant immunotherapy in high-risk melanoma of the extremities.. PubMed. 92(3). 459–63.22 indexed citations
12.
Kk, Chan, et al.. (1980). Metabolism of methotrexate in man after high and conventional doses.. PubMed. 28(3). 551–61.15 indexed citations
13.
Ms, Mitchell. (1978). Immunological methods in diagnosis and monitoring of head and neck cancer.. PubMed. 88(1 Pt 2 Suppl 8). 18–9.
14.
Lundy, Joel, et al.. (1978). Pulmonary granulomas in a patient on MER therapy.. PubMed. 50(6). 665–8.3 indexed citations
15.
Ms, Mitchell, et al.. (1977). Transient warm autoimmune hemolytic anemia and cryoglobulinemia associated with seminoma.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 50(4). 419–27.8 indexed citations
16.
Ms, Mitchell, et al.. (1976). Cell-mediated immunity and blocking factor in ovarian carcinoma.. PubMed. 48(5). 590–7.21 indexed citations
17.
Ms, Mitchell. (1976). Studies on the immunogical effects of BCG and its components: theoritical and therapeutic implications.. PubMed. 24(4). 209–13.5 indexed citations
18.
Levitt, Martin, et al.. (1973). Improved therapeutic index of methotrexate with "leucovorin rescue".. PubMed. 33(7). 1729–34.123 indexed citations
19.
Levitt, Martin, et al.. (1970). The Yale combination chemotherapy program for advanced Hodgkin's disease. A preliminary report.. PubMed. 34(12). 862–6.2 indexed citations
20.
Ms, Mitchell, et al.. (1968). Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.. PubMed. 28(6). 1088–94.48 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.